CHRS Coherus BioSciences Inc.

Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th

Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th

REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021. The news release will be followed by an investor conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.

Conference Call Information

When: Wednesday, February 24, 2021 starting at 4:30 p.m. ET

Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)

Conference ID: 3770488

Webcast:

Please join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.

About Coherus BioSciences

is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system.

For additional information, please visit .

Contact

McDavid Stilwell

EVP, Financial Strategy and IR

Coherus BioSciences, Inc.



+1 (650) 395-0152



EN
18/02/2021

Underlying

CHRSCoherus BioSciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Participate in Upcoming Investor Conferences

Coherus Oncology to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus Oncology website: . A replay of the presentation will be available on this same website for approximately 90 days. 46th Annual TD Cowen Healthcare Conference in Boston, on Wednesday, March 4, 2026, at 11:50 a.m. Eastern Da...

19h / 12m 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology, Inc. Announces Closing of Public Offering of Common ...

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock –The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the closing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock were sold at a public offering price of $1.75 per share, before underwriting discounts and ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common ...

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock are being sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All of the shares in the Offering are being sold by the Company. The gross proceeds to Coherus from the Offering are expected t...

February 13, 2026 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology, Inc. Announces Proposed Public Offering of Common St...

Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced a proposed underwritten public offering of its common stock (the “Offering”). In addition, Coherus intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the Offering, at the public offering price per share less underwriting discounts and commissions. All of the shares in the Offering ar...

February 12, 2026 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcar...

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: . This webcast will be available for replay until February 13, 2026. About Coherus OncologyCoherus Onco...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch